Latest Blog Posts Tagged "Austria"
September 07, 2016
Austrian biotech AFFiRiS reports a boost dose of its vaccine against key protein alpha-synuclein is safe and elicits antibodies. MJFF funded the trial.
December 16, 2014
Biotech AFFiRiS has begun a clinical trial for a new vaccine (PD03A) to treat Parkinson's. This builds on the success of the MJFF-funded trial of the company's first PD vaccine candidate (PD01A).
July 31, 2014
The Austrian biotech AFFiRiS AG announced positive results of its Phase I safety trial of a vaccine against alpha-synuclein, a treatment that could slow or stop Parkinson's disease .
April 29, 2014
Results from the first study on Parkinson's disease vaccine drug candidates are expected later this year.
The Michael J. Fox Foundation Expands Fox Trial Finder to Help Accelerate Parkinson's Trials Worldwide
November 14, 2013
Fox Trial Finder, MJFF's online clinical matching tool, is now global! The expansion will grow the clinical research community worldwide and encourage more people to participate.
Three Questions for a Researcher with Markus Mandler, PhD, Head of the Neurodegeneration Department at AFFiRiS AG
May 09, 2013
Markus Mandler's team at AFFiRiS AG is currently testing a vaccine called PD01, the first Parkinson's drug to target alpha-synuclein to make it to the clinic.
March 28, 2013
Officially launched in 2012 to help increase the flow of participants into clinical trials that urgently need more people, Fox Trial Finder aims high in 2013 — to attain 30,000 volunteers.
June 05, 2012
For many, the decision to participate in genetic research is not a trivial one. But for Gary Schmitz, he didn't think twice. "For me," he says, "the question was why wouldn't you want to contribute?"